Placebo effect on progression and regression in NASH: Evidence from a meta-analysis,Hepatology

当前位置： X-MOL 学术 › Hepatology › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Placebo effect on progression and regression in NASH: Evidence from a meta-analysis
Hepatology ( IF 12.9 ) Pub Date : 2022-01-06 , DOI: 10.1002/hep.32315
Cheng Han Ng ₁ , Jieling Xiao ₁ , Wen Hui Lim ₁ , Yip Han Chin ₁ , Jie Ning Yong ₁ , Darren Jun Hao Tan ₁ , Phoebe Tay ₁ , Nicholas Syn ₁ , Roger Foo _{1,

2} , Mark Chan _{1,

2} , Nicholas Chew _{1,

2} , Eunice Xx Tan _{1,

3,

4} , Daniel Q Huang _{1,

3,

4} , Yock Young Dan _{1,

3,

4} , Nobuharu Tamaki ₅ , Mohammad Shadab Siddiqui ₆ , Arun J Sanyal _{7,

8} , Rohit Loomba ₅ , Mazen Noureddin ₆ , Mark D Muthiah _{1,

3,

4}

Affiliation

The evaluation of the natural history of NASH has been limited. Currently, liver biopsy remains the gold standard in the assessment of NASH. Placebo-controlled trials represent a controlled environment with paired biopsies for the evaluation of NASH. This meta-analysis thus seeks to quantify the change severity of NASH over time, with patients on placebo arms from randomized controlled trials (RCTs) to examine the natural history of NASH.

中文翻译：

安慰剂对 NASH 进展和消退的影响：来自荟萃分析的证据

NASH 自然史的评估有限。目前，肝活检仍然是评估 NASH 的金标准。安慰剂对照试验代表了用于评估 NASH 的配对活检的受控环境。因此，这项荟萃分析旨在量化 NASH 随着时间的推移而变化的严重程度，其中安慰剂组的患者来自随机对照试验 (RCT)，以检查 NASH 的自然史。

更新日期：2022-01-06

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11